A company in Minnesota says it has developed a cannabis vaporization system that meets Food and Drug Administration (FDA) requirements.
According to VCT, the process for vaporizing plant oils is consistent, reliable, precise, environmentally friendly, and cost-effective.
VCT says its new technology will cause a change in medical and adult-use cannabis markets.
A VCT spokesperson says the new technology will become the medical standard for ingesting cannabinoids in vapor form once commercialized.
“It promises to be the only technology that can provide the dose control, formulation control, and purity assurance of inhaled botanical vapors required of an FDA-approved drug,” states a VCT press release. “This technology will result in a paradigm shift in both the medical and recreational cannabis markets.”
Having observed veterans with PTSD and commit suicide for decades, VCT Owner Tim McCullough found that pilot studies showed cannabis as a promising treatment.
With no FDA-approved smoke-free cannabinoid delivery method, McCullough set out on a mission in 2013 to invent one.
A former 3M engineer, McCullough worked intently in his research and inventing.
McCullough’s work resulted in a patented FDA-approvable process for extracting botanical oils and resins from plants.
VCT says it is searching for licensing opportunities for its new technology and have launched a data-rich website to help accomplish its goals.
The website presents detailed explanations of the new VCT technology’s science, competitive analysis, benefits, patent portfolio, potential licensees, and contact information.